Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA

Abstract

SummaryPharmacologic therapy is recommended to reduce future fracture risk. We examined osteoporosis medications dispensed to older women after first fracture. Only 23 % received therapy during the first year post-fracture. Prior osteoporosis therapy, a prior osteoporosis diagnosis, and older age were good predictors of post-fracture osteoporosis therapy.IntroductionPharmacologic therapy is recommended after osteoporotic fracture to reduce future fracture risk. The objective of this retrospective study was to examine osteoporosis therapy dispensed to women post-fracture.MethodsWe identified women ≥50 years old in a large administrative claims database from 2003 to mid-2012 who were continuously enrolled 2 years before (baseline) and 1 year after first osteoporotic fracture. Exclusions were Paget’s disease or malignant neoplasm. Pre- and post-fracture osteoporosis therapies (oral and parenteral) were assessed overall and by fracture site.ResultsA total of 47,171 women of mean (SD) age of 63 (10) years were eligible; fractures included 8 % hip, 17 % vertebral, 73 % non-hip/non-vertebral, and 3 % multiple fracture sites. Only 18 % received osteoporosis therapy within 90 days and 23 % within 1 year post-fracture. Overall, 19 % of women had a prior osteoporosis diagnosis; 20 % had received osteoporosis therapy during baseline. Of 37,649 (80 %) women without baseline therapy, only 9 % initiated pharmacologic therapy within 1 year. The adjusted odds ratio (OR) of therapy within 1 year post-fracture was significantly greater for women who had received baseline osteoporosis therapy (versus none) and who had vertebral (OR 12.7, 95 % confidence interval (CI) 11.2–14.5), hip (15.2, 12.5–18.7), or non-hip/non-vertebral fracture (34.4, 31.7–37.3). Other significant predictors included pre-fracture osteoporosis diagnosis (1.6, 1.4–1.7) and older age (OR range, 1.3–1.7). Treatment adherence was significantly better among women with baseline osteoporosis diagnosis.ConclusionsThe substantial post-fracture treatment gap represents an important unmet need for women with osteoporotic fractures. Fracture liaison or adherence programs could lead to improved post-fracture treatment rates.Electronic supplementary materialThe online version of this article (doi:10.1007/s00198-014-2827-x) contains supplementary material, which is available to authorized users.

One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study

“…After a fracture, the risk of second fracture is five times higher in the next year, and recent fracture and other characteristics such as older age and low bone mineral density (BMD) can put patients at high risk for fracture both over a longer‐term horizon (eg, 10 years), as well as over shorter‐term horizons . However, even in patients in whom there is urgency to treat, there is a large treatment gap in osteoporosis, with only about 20% of patients receiving treatment following a fracture . Limited options for bone‐forming therapy are currently available.…”

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

“…1,2 Even after a fracture, fewer than 25% of patients receive pharmacologic treatment for osteoporosis. [3][4][5] After the discovery that sclerostin deficiency causes rare genetic conditions that are characterized by high bone mass and resistance to fracture, 6,7 sclerostin became a therapeutic target for the treatment of osteoporosis. Sclerostin, a negative regulator of bone formation that is secreted by osteocytes, 8 inhibits Wnt signaling, down-regulating this stimulus for osteoblast development and function.…”

A Survey of Women's Awareness of and Reasons for Lack of Postfracture Osteoporotic Care

“…Clinical guidelines recommend pharmacotherapy (RX) with demonstrated efficacy in the management of OP and in the prevention of fracture for individuals at high risk of fracture, but treatment rates are suboptimal. Studies report that only 20% to 25% of individuals undergo OP‐RX in the 6 to 12 months after a fragility fracture …”